

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Approval Package for:**

***APPLICATION NUMBER:***  
**021928Orig1s014**

***Trade Name:*** CHANTIX

***Generic or  
Proper Name:*** varenicline tartrate

***Sponsor:*** Pfizer, Inc.

***Approval Date:*** 04/22/2010

***Indication:*** CHANTIX is a nicotinic receptor partial agonist indicated for use as an aid to smoking cessation treatment.

# CENTER FOR DRUG EVALUATION AND RESEARCH

**APPLICATION NUMBER:  
NDA 021928/S-014**

## CONTENTS

### Reviews / Information Included in this NDA Review.

<b>Approval Letter</b>	<b>X</b>
<b>Other Action Letters</b>	
<b>Labeling</b>	<b>X</b>
<b>REMS</b>	
<b>Summary Review</b>	
<b>Officer/Employee List</b>	
<b>Office Director Memo</b>	
<b>Cross Discipline Team Leader Review</b>	
<b>Medical Review(s)</b>	
<b>Chemistry Review(s)</b>	
<b>Environmental Assessment</b>	
<b>Pharmacology Review(s)</b>	
<b>Statistical Review(s)</b>	
<b>Microbiology Review(s)</b>	
<b>Clinical Pharmacology/Biopharmaceutics Review(s)</b>	
<b>Other Reviews</b>	<b>X</b>
<b>Risk Assessment and Risk Mitigation Review(s)</b>	
<b>Proprietary Name Review(s)</b>	
<b>Administrative/Correspondence Document(s)</b>	<b>X</b>

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*  
**NDA 021928/S-014**

**APPROVAL LETTER**



NDA 021928/SLR-014, SLR-017

**SUPPLEMENT APPROVAL**

Pfizer, Inc.  
235 East 42<sup>nd</sup> Street  
Mailstop 605 6 31  
New York, NY 10017

Attention: Lilya I. Donohew, Ph.D.  
Director, Worldwide Regulatory Affairs

Dear Dr. Donohew:

Please refer to your supplemental new drug applications dated July 20, 2009, and January 14, 2010, received July 20, 2009, and January 14, 2010, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Chantix (varenicline) Tablets 0.5 mg and 1 mg.

We acknowledge receipt of your submissions dated February 17, 2010 (S-017) and February 25, 2010 (S-014).

Supplement NDA 021928/S-014 proposes conversion of the content of the currently approved package insert into the Physicians Labeling Rule (PLR) format as set forth under 21 CFR 201.56 and 21 CFR 201.57.

We also refer to the email correspondences between FDA and Pfizer dated March 16, 2010, in which agreement was reached on content of the package insert in the PLR format.

Supplement NDA 021928/S-017 provides for a proposed modification to the approved risk evaluation and mitigation strategy (REMS) and includes your REMS assessment.

We have completed our review of these applications, as amended, and they are approved, effective on the date of this letter, for use as recommended in the enclosed agreed upon labeling text for the package insert, Medication Guide and modified REMS.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)(1)(i)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to the enclosed labeling text for the package insert and Medication Guide). For administrative purposes, please designate this submission, "SPL for approved NDA 21928/S-014 and S-017.

We request that the revised labeling approved today be available on your website within 10 days of receipt of this letter.

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

### **RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS**

The REMS for Chantix (varenicline) was originally approved on October 19, 2009. The REMS consists of a Medication Guide and a timetable for submission of assessments of the REMS. The proposed modified REMS contains a revised Medication Guide that includes a new section "Who should not take Chantix".

Your proposed modified REMS, submitted on January 14, 2010, and appended to this letter, is approved. The REMS consists of the Medication Guide and the timetable for submission of assessments.

The timetable for submission of assessments will remain the same as that approved on October 19, 2009.

There are no changes to the REMS assessment plan described in our October 19, 2009 letter.

If you do not submit electronically, please send 5 copies of REMS-related submissions.

### **PROMOTIONAL MATERIALS**

All promotional materials for your drug product that include representations about your drug product must be promptly revised to make it consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions to your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the following address or by facsimile at 301-847-8444:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

In addition, as required under 21 CFR 314.81(b)(3)(i), you must submit your updated final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA-2253, directly to the above address. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.